We're building multiple technologies for targeted protein degradation and at the American Association of Immunologists Annual Meeting later this week, we'll present preclinical data on MTACs, a platform that expands our degradation capabilities and complements our ATAC degrader technology. #AAI2024 #AvilarGoesExtracellular
Avilar Therapeutics
Biotechnology
Waltham, MA 2,047 followers
Pioneering the discovery and development of extracellular protein degraders.
About us
Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degrader therapeutics that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA.
- Website
-
http://www.avilar-tx.com/
External link for Avilar Therapeutics
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Waltham, MA
- Type
- Privately Held
Locations
-
Primary
Get directions
Waltham, MA, US
Employees at Avilar Therapeutics
Updates
-
On #administrativeprofessionals day, we want to recognize our exceptional colleague Karen for all she does at Avilar. Thank you for your dedication and for your hard work!
-
-
Please join us in welcoming Jorge to the Avilar team! We're happy to have him on board to help us advance our novel extracellular protein degraders as potentially transformative medicines for patients. #AvilarGoesExtracellular #Team
-
-
We're honored to have an amazing group of women at Avilar helping advance our extracellular protein degraders as potential medicines that dramatically improve care for patients. We can't do it without you! #IWD2024 #InspireInclusion
-
-
Today is #EmployeeAppreciationDay and we're showing our gratitude for our amazing team members who give it their all - every day of the year. #AvilarGoesExtracellular
-
-
Today we acknowledge and honor the incredible contributions of the women at Avilar who are driving innovation and inspiring the next generation. #February11th #STEM #WomenandGirlsinScience #InspiringInnovation #AvilarGoesExtracellular
-
-
Avilar welcomed the new year with a fun and festive team event. We're looking forward to an exciting 2024! #AvilarGoesExtracellular
-
-
We are thrilled to welcome Alonso to our Scientific Advisory Board. He has over a decade of drug discovery and development experience leading programs across multiple therapeutic areas, including immunology, metabolic diseases, and oncology. #AvilarGoesExtracelluar https://lnkd.in/etKuy8VC
-
-
After a recent strategic team offsite, we rolled up our sleeves and got creative on canvas. The Boston skyline never looked so good! #AvilarGoesExtracellular
-